Our legal team is currently examining cases involving Mounjaro lawsuits concerning patients with gallbladder disease or gastrointestinal issues such as gastroparesis or cyclic vomiting syndrome.
Mounjaro, known as semaglutide in its generic form, is a popular prescription medication used for managing type-2 diabetes and weight control. Recent research has indicated that the use of Mounjaro, especially in higher doses, may cause several serious health conditions. The health conditions linked to Mounjaro include gastroparesis (stomach paralysis), and other stomach conditions, gallbladder disease, and vision loss.
If you took Mounjaro for weight loss and suffered gallbladder or gastrointestinal problems, contact us for a free case evaluation. Call us at 800-553-8082 or contact us online.
We Are Accepting Mounjaro Cases for 8 Types of Injuries
Our Mounjaro lawyers are currently accepting new Mounjaro lawsuits from plaintiffs who have taken the drug and suffered one of the following 8 specific injuries:
- Gastroparesis
- Gastrointestinal Problems Causing Hospitalization
- Esophageal Damage Resulting in Surgery
- Bowel Obstruction
- NAION Vision Loss
- DVT (blood clot)
- Pulmonary Aspiration
- Gallbladder Disease (With Surgery)
About Mounjaro
Mounjaro is a medication specifically developed for the treatment of Type 2 diabetes. Administered via a weekly under-the-skin injection, it belongs to a class of antidiabetic drugs that operate by stimulating the production and release of certain intestinal hormones, thereby prompting the body to release insulin.
Eli Lilly, one of the leading pharmaceutical companies globally, holds the patent for Mounjaro. Approved for medical use in the United States as recently as May 2022, Mounjaro was a groundbreaking new drug, one of the first of its kind to win FDA approval.
Although initially approved solely for diabetes treatment, Mounjaro has recently gained popularity among healthcare professionals for its potential to manage weight loss in obese patients. This “off-label” use for weight loss mirrors similar trends observed with diabetes medications like Ozempic and Wegovy.
Mounjaro Causes Gallbladder, Gastrointestinal, and Vision Problems
An expanding body of clinical research indicates that the use of Mounjaro can lead to severe gastrointestinal and gallbladder complications. The risk of encountering these issues is particularly high when Mounjaro is used for weight loss purposes, especially at higher dosages. New evidence has also linked the use of Mounjaro to NAION (nonarthritic anterior ischemic optic neuropathy) a condition which causes sudden vision loss.
Mounjaro has been associated with the onset of several serious and potentially life-threatening health conditions, including:
– Gastroparesis: Referred to as “stomach paralysis,” this medical condition entails abnormal muscle movement in the stomach, resulting in slowed or halted stomach motility and improper emptying. Gastroparesis can lead to significant discomfort and potentially serious complications.
– Gastroenteritis: Characterized by infection and inflammation within the digestive system, gastroenteritis manifests with symptoms such as stomach cramps, diarrhea, and vomiting. Dehydration is a primary concern associated with this condition.
– Gallbladder Disease: Mounjaro and similar medications have been linked to the development of gallbladder disease, involving chronic inflammation of the gallbladder and the formation of gallstones. This condition can be highly painful and may necessitate surgical removal of the gallbladder.
–NAION: A very recent scientific study has found that using Mounjaro and similar drugs can increase the risk of a condition called non-arteritic anterior ischemic optic neuropathy (NAION). This condition is trigger by a lack of blood flow to the optic nerve and it can cause vision loss.
The FDA has recently issued a major “boxed” warning regarding Mounjaro, emphasizing its potential association with gallbladder disease. This type of warning signifies the highest level of alert issued by the FDA. Anyone who started using Mounjaro after the new black box warning will likely not be able to bring a lawsuit.
Mounjaro Causes Gastroparesis
There is strong scientific evidence showing that prolonged use of drugs like Mounjaro can cause serious gastrointestinal health problems. The most dangerous gastrointestinal health condition caused by Mounjaro is gastroparesis. Gastroparesis, also known as “stomach paralysis,” is a condition where the muscles in the digestive system that move food through the system basically stop working or become very slow-moving.
Gastroparesis can be a very serious condition. It causes your body to basically stop digesting food at a normal rate. This can result in severe abdominal pain, bloating, fatigue, dehydration, and other problems. There is no easy treatment option to correct gastroparesis. Medication is usually the first option, with surgery reserved for the most severe cases.
Mounjaro Causes NAION Vision Loss
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), also known as an “eye stroke” is a condition that happens when the flow of blood to the optic nerve is cut off or restricted. The lack of blood supply causes damage to cells in the optic nerve which causes vision loss and impairment. In many cases, the vision loss from NAION is permanent.
A brand new study, published in June 2024, reported that prolonged use of drugs like Mounjaro can trigger NAION. Diabetes drugs like Mounjaro can cause rapid imbalances in blood sugar levels. These acute changes in blood sugar can interrupt the flow of blood to the optic nerve, which triggers NAION.
Although the evidence linking Mounjaor to NAION is new and not well established, the scientific evidence appears to be solid. Assuming this evidence is deemed admissible in court, NAION could end up being the most serious injury in the Mounjaro lawsuits.
Mounjaro Causes DVT Blood Clots
Deep vein thrombosis (DVT) is a condition in which a blood clot forms in a deep vein, typically in the legs, and can be dangerous if the clot travels to the lungs, leading to a pulmonary embolism (PE). DVT risk factors include prolonged immobility, surgery, certain medications, and conditions that affect blood clotting. While tirzepatide has demonstrated significant benefits in managing blood glucose and weight loss in patients with type 2 diabetes, its impact on DVT risk has not been a major focus in studies.
So unlike Ozempic and Wegovy, Mounjaro has not been commonly associated with an increased risk of deep vein thrombosis in clinical trials or studies. While semaglutide has been noted in some studies to have a potential link to DVT, tirzepatide’s cardiovascular safety profile appears favorable so far. The primary concerns with tirzepatide in clinical studies have focused on its gastrointestinal side effects but not DVT. Our law firm is still looking at Mounjaro DVT cases because we do not think the evidence is conclusive. But there is no question that the Ozempic DVT cases are stronger.
Mounjaro Lawsuits
An increasing number of product liability lawsuits concerning Mounjaro are currently underway, and more are getting filed. These legal actions are being filed by individuals who took Mounjaro for weight loss and subsequently experienced some of the gastrointestinal or gallbladder complications detailed above.
The primary basis for these Mounjaro lawsuits is that the manufacturer negligently failed to provide adequate warning about the risks of gallbladder and gastrointestinal injuries. Plaintiffs assert that Eli Lilly was aware, or should have been aware, of the potential health risks, such as gastroparesis or gallbladder disease, associated with regular usage of Mounjaro at higher doses. Despite this awareness, the lawsuits contend that Eli Lilly neglected to include any warnings regarding these specific risks on Mounjaro’s drug label. Consequently, both healthcare professionals and patients were unaware of the potential dangers linked to Mounjaro use.
Mounjaro Class Action Lawsuit
In February 2024, all of the product liability lawsuits involving gallbladder and gastrointestinal injuries caused by Mounjaro (and its sister drugs Ozempic and Wegovy) were consolidated into a new “class action” MDL. The new Mounjaro MDL was assigned to Judge Gene E.K. Pratter in the Eastern District of Philadelphia.
The creation of the MDL means that all future Mounjaro lawsuits filed in federal courts around the country will be transferred into the MDL. Judge Pratter will oversee a process of consolidated or “group” discovery handled by a group of plaintiffs’ lawyers appointed to a committee. At the end of that discovery phase, a handful of sample cases will be selected for bellwether test trials. The result of these test trials are supposed to help the parties value the cases for settlement purposes.
Side Effects of Mounjaro
Mounjaro may induce various side effects, with some being more prevalent than others. While many of these side effects are transient and may persist for a few days to weeks, it’s crucial to address any prolonged, bothersome, or severe symptoms by consulting your doctor or pharmacist. The following are the most common Mounjaro side effects:
nausea
diarrhea
appetite loss
vomiting
constipation
Potential Settlement Value of Mounjaro Lawsuits
At this very premature stage of the litigation, accurately predicting the settlement value of Mounjaro lawsuits is very challenging. A significant factor contributing to this uncertainty is the question of whether the scientific evidence supporting these cases will withstand scrutiny in court, as is typical in pharmaceutical litigation.
Given these uncertainties, any estimations regarding settlement amounts or potential jury awards for Mounjaro lawsuits must be viewed as highly speculative. However, our legal team can provide an informed estimate based on certain assumptions about the case’s progression. Understanding that individuals seek insights into the potential outcomes, we aim to offer our perspective, albeit based on speculative assumptions.
With this context in mind, our attorneys suggest that a successful Mounjaro lawsuit could potentially yield a settlement value ranging from $150,000 to $300,000. This estimation is comparatively lower than our valuation for Ozempic lawsuits, primarily due to the shorter time Mounjaro has been on the market. Consequently, Mounjaro plaintiffs may have had less exposure to the drug compared to Ozempic plaintiffs, potentially weakening the strength of their cases.
Get a Mounjaro Lawyer
Mounjaro lawsuits are being filed around the country. If you have a Mounjaro lawsuit, call our attorneys today at 800-553-8082 or reach out to us online.